Plasma Hydrogen Sulfide Is Positively Associated With Post-operative Survival in Patients Undergoing Surgical Revascularization.

Hydrogen sulfide (HS) is a gaseous signaling molecule and redox factor important for cardiovascular function. Deficiencies in its production or bioavailability are implicated in atherosclerotic disease. However, it is unknown if circulating HS levels differ between vasculopaths and healthy individuals, and if so, whether HS measurements can be used to predict surgical outcomes. Here, we examined: (1) Plasma HS levels in patients undergoing vascular surgery and compared these to healthy controls, and (2) the association between HS levels and mortality in a cohort of patients undergoing surgical revascularization. One hundred and fifteen patients undergoing carotid endarterectomy, open lower extremity revascularization or lower leg amputation were enrolled at a single institution. Peripheral blood was also collected from a matched control cohort of 20 patients without peripheral or coronary artery disease. Plasma HS production capacity and sulfide concentration were measured using the lead acetate and monobromobimane methods, respectively. Plasma HS production capacity and plasma sulfide concentrations were reduced in patients with PAD ( < 0.001, = 0.013, respectively). Patients that underwent surgical revascularization were divided into high vs. low HS production capacity groups by median split. Patients in the low HS production group had increased probability of mortality ( = 0.003). This association was robust to correction for potentially confounding variables using Cox proportional hazard models. Circulating HS levels were lower in patients with atherosclerotic disease. Patients undergoing surgical revascularization with lower HS production capacity, but not sulfide concentrations, had increased probability of mortality within 36 months post-surgery. This work provides insight on the role HS plays as a diagnostic and potential therapeutic for cardiovascular disease.